06622 ZHAOKE OPHTH-B
- 1.560
- +0.040+2.63%
ZHAOKE OPHTH-B News
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
Zhaoke Ophthalmology Shrinks Loss in 2023
Zhaoke Ophthalmology (HKG:6622) recorded a decline in attributable loss for the year ended Dec. 31, 2023, to 385 million yuan from 407.3 million yuan in 2022, according to the company's annual report
兆科眼科-B：2023 年報
Zhaoke Ophthalmology-B (06622.HK): Chen Yu resigns as non-executive director
Zhaoke Ophthalmology-B (06622.HK) announced that Chen Yu has resigned as a non-executive director to spend more time on other work arrangements, effective April 8, 2024.
Annual Report Observation: The second low-concentration atropine produced in China is coming, and the value of Zhaoke Ophthalmology-B (6622.HK) has been rediscovered
The innovative ophthalmology drug market has always been one of the hot areas that the market has paid great attention to, especially in the field of myopic ophthalmology.
Zhaoke Ophthalmological-B (06622.HK) announces annual results, first confirmation that sales revenue is continuing to expand its footprint globally
Gelonghui, March 27 | Zhaoke Ophthalmology-B (06622.HK) announced that the company first confirmed sales revenue in 2023: in 2023, the company recorded total revenue of RMB 18.8 million, of which RMB 4.7 million came from the sale of ophthalmic drugs (including bemesol timolol and Ruibault), while RMB 8.4 million came from the sale of non-prescription ophthalmic products (Baudexi series hot eye masks). Additionally, the company recorded revenue of RMB 5.6 million from distribution transaction payments outside of China. The company's pipeline is equipped with a variety of key innovative drugs that may have significant curative effects, which can be expected in the future
ZHAOKE OPHTH-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Zhaoke Ophthalmology-B (06622.HK) was granted FIDELITY CHINA SPECIAL EXCLUSIVE PLC to increase its common shares by 2,822 million shares worth approximately HK$4,573,900
On March 22, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on March 22, FIDELITY CHINA SPECIAL ATTRACTION PLC increased its share holdings of $Zhaoke Ophthalmology-B (06622.HK) by $2,822,000 at an average price of HK$1.6208 per share on March 19, worth approximately HK$4.573,900. After the increase in holdings, FIDELITY CHINA SPECIAL PROVIDES PLC's latest shareholding number was 32.974 million shares, and the good position ratio increased from 5.52% to
Zhaoke Ophthalmology-B (06622.HK) held a board meeting on March 27 to consider and approve annual results
Gelonghui March 15 | Zhaoke Ophthalmology-B (06622.HK) announced that the board of directors meeting will be held on March 27, 2024 (Wednesday) to consider and approve (among other things) the annual results of the company and its subsidiaries for the year ended December 31, 2023 and their publication.
At a time of market fluctuations, some opinions on the listing process of Zhaoke Ophthalmology-B (6622.HK) NVK002
As an investor who has been following the innovative medicine sector of Hong Kong stocks for a long time, the Hong Kong stock capital market has continued to be sluggish recently, showing a rare situation of continuous decline. Shareholders have begun to panic, causing many high-quality companies to be affected.
Changes in Hong Kong stocks | Zhaoke Ophthalmology-B (06622) plummeted 31% in the afternoon and previously announced that the FDA designated low-concentration atropine for approval at the end of January
Zhaoke Ophthalmology-B (06622) plummeted 31% in the afternoon. As of press release, it fell 28.43% to HK$2.14, with a turnover of HK$8.7396 million.
Zhaoke Ophthalmology Grants Kwangdong Pharma Rights to Distribute Eye Drop in Korea
Zhaoke Ophthalmology (HKG:6622) said Zhaoke (Hong Kong) Ophthalmology Pharmaceutical has signed a distribution and supply agreement with South Korea's Kwangdong Pharmaceutical (KRX:009290). The agreem
Changes in Hong Kong stocks | Zhaoke Ophthalmology-B (06622) rose more than 3% to grant exclusive distribution rights for BRIMOCHOL PF in Korea to KDP
The Zhitong Finance App learned that Zhaoke Ophthalmology-B (06622) rose by more than 3%. As of press release, it had risen 3.61% to HK$3.16, with a turnover of HK$1,140,900. According to the news, Zhaoke Ophthalmology announced today that Zhaoke (Hong Kong) Ophthalmology Co., Ltd. (a wholly-owned subsidiary of the company) and Kwangdong PharmaceuticalCo. , Ltd. (KDP, a leading Korean company mainly engaged in pharmaceutical production and distribution) does not contain prophylaxis for BRIMOCHOLPF (2.75% carbaco/ 0.1% bromonidine tartrate 0.1% fixed-dose compound)
Zhaoke Ophthalmology-B (06622.HK): Distribution agreement with KWANGDONG PHARMACEUTICAL for commercialization of BRIMOCHOL PF in Korea
On January 29, Ge Longhui Ophthalmology-B (06622.HK) announced that Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Co., Ltd. (a wholly-owned subsidiary of the Company) and Kwangdong Pharmaceutical Co., Ltd. (“KDP”, a leading Korean company mainly engaged in pharmaceutical production and distribution) have entered into a distribution and supply agreement for BRIMOCHOL PF (2.75% carbaco/ 0.1% bromonidine tartrate) fixed-dose eye drops without preservatives. According to the terms of the agreement, the company has the right to exclusively distribute this product in Korea
Changes in Hong Kong stocks | Zhaoke Ophthalmology-B (06622) rose more than 6% and clinical trial applications for two new drugs to treat presbyopia were approved
Zhaoke Ophthalmology-B (06622) rose more than 6%. As of press release, it rose 6.6% to HK$3.07, with a turnover of HK$1,148,800.
Changes in Hong Kong stocks | Zhaoke Ophthalmology-B (06622) raised 5% in the afternoon to apply for clinical trials of two new drugs to treat presbyopia, approved by the China Drug Administration
The Zhitong Finance App learned that Zhaoke Ophthalmology-B (06622) rose 5% in the afternoon. As of press release, it had risen 5% to HK$2.94, with a turnover of HK$1,090,800. According to the news, Zhaoke Ophthalmology announced that new drug test applications for BRIMOCHOL PF and CARBACHOL PF have recently been approved by China's National Drug Administration. Based on the “Drug Clinical Trial Approval Notice” approved by the State Drug Administration, the company will conduct clinical trials on presbyopia subjects in China. According to the announcement, BRIMOCHOL PF and Carbachol PF are preservative-free
Featured Announcements | New Oriental: Net profit for FY2024 Q2 surged more than 40 times year on year; Oriental Selection: Net profit for mid-fiscal year 2024 fell nearly 60% year on year
China Railway Construction: The total amount of new contracts signed in 2023 was 3.29 trillion yuan, an increase of 1.51% over the previous year; Cathay Pacific: Passenger capacity for the full year of 2023 exceeded 20 million yuan.
Zhaoke Ophthalmology-B (06622.HK): Clinical trial applications for BRIMOCHOL PF and CARBACHOL PF new drugs for the treatment of presbyopia were approved by the National Drug Administration
On January 24, Gelonghui | Zhaoke Ophthalmology-B (06622.HK) announced that BRIMOCHOL PF and Carbachol PF new drug test applications have recently been approved by the China National Drug Administration (“State Drug Administration”). Based on the “Drug Clinical Trial Approval Notice” approved by the State Drug Administration, the company will conduct tests on presbyopia subjects in China.
Zhaoke Ophthalmology's Myopia Treatment Shows Strong Safety, Efficacy in Phase 3 Study
Phase 3 clinical trials for Zhaoke Ophthalmology's (HKG:6622) NVK002 myopia treatment for children performed by its US partner Vyluma showed strong safety and efficacy, according to a Friday filing. T
Zhaoke Ophthalmology-B (06622): NVK002 has strong safety and efficacy as a potential treatment for deepening myopia in children
Zhaoke Ophthalmology-B (06622) released NVK002 (one of the company's core products) in its one-year phase III...
Analysis
Price Target
No Data
